announced results from a Phase 2, randomized, placebo-controlled trial evaluating two doses of GS-0976, an oral, investigational inhibitor of Acetyl-CoA carboxylase, in patients with nonalcoholic steatohepatitis
Neuschwander-Tetri, "Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis
: the central role of nontriglyceride fatty acid metabolites," Hepatology, vol.
Seki, "Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis
through inflammasome activation in mice," Hepatology, vol.
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
. N Engl J Med.
The US National Institute of Diabetes and Digestive and Kidney Diseaeses has more about nonalcoholic steatohepatitis
The natural history of nonalcoholic steatohepatitis
: A follow-up study of forty-two patients for up to 21 years.
INVESTIGATORS, looking into earlier findings that suggested a connection between antioxidants, thiazolidinedione (TZD) medications, and improvements in nonalcoholic steatohepatitis
(NASH), conducted a multicenter double-blind trial enrolling 247 nondiabetic patients.
ISLAMABAD, May 11, 2010 (Balochistan Times): A daily dose of a specific form of vitamin E can improve nonalcoholic steatohepatitis
(NASH), a liver disease.
A daily dose of a specific form of vitamin E significantly improved the liver disease, nonalcoholic steatohepatitis
(NASH), according to a study funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health.
. Mayo clinic experiences with a hitherto unnamed disease.
This reference provides basic consumer health information about all types of hepatitis, including autoimmune hepatitis, nonalcoholic steatohepatitis
, and toxin-induced hepatitis.
NEW ORLEANS -- Fatty liver disease and nonalcoholic steatohepatitis
have become increasingly common with rising obesity rates, Dr.